AEON

Healthcare Biotechnology

AEON Biopharma, Inc.

$0.27

+0.01 +3.01% today

Price History

Not enough data

Key Stats

Market Cap

13.47M

Avg Volume

8.37M

EPS

-$4.39

52W High

$1.45

52W Low

$0.18

Div. Yield

0.0%

Analyst Ratings

Buy

Str Buy

Buy

Hold

Sell

Str Sell

Valuation

Forward P/E

-1.00

P/B Ratio

-0.46

EV/EBITDA

-0.65

Margins

Gross Margin 0.0%

Operating Margin 0.0%

Net Margin 0.0%

EBITDA Margin 0.0%

Growth & Returns

Return on Assets

(141.5%)

Liquidity & Leverage

Current Ratio

0.54

Quick Ratio

0.47

Total Cash

3.43M

Total Debt

2.77M

About

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine. It also develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceutical Co., LTD., and Viatris Inc. The company is based in Irvine, California.